Medication info

Ilyang Dapagliflozin 5 mg Tablets (Dapagliflozin Monohydrate)

Prescription medicationTabletOralExpired
Ingredient · strength
Dapagliflozin Anhydrous Lactose Mixture›7.635mg / 1 tablet
Manufacturer / importer
Ilyang Pharmaceutical Co., Ltd.
Appearance
Yellow, round, film-coated tablet with convex sides on both sides
Packaging
28 tablets/box [28 tablets (7 tablets/PTP×4)]
Approval status
Expired

MFDS item code 202005358 · Approved 2020.07.23

This product's status changed to Expired on 2025.07.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults · Children
Adult dose
Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, when this medicine is administered in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.
Child dose
The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Ingredients

Manufacturer
Ilyang Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used as an adjunct to dietary and exercise therapies to improve blood sugar control in patients with type 2 diabetes. It can be administered as monotherapy and, if blood sugar control is insufficient, it can be used in combination with other diabetes treatments such as metformin, sulfonylureas, insulin, or sitagliptin. Especially, for patients who have not previously received diabetes drug therapy or when monotherapy is ineffective, combination therapy can more effectively control blood sugar levels. This medication helps manage type 2 diabetes effectively through combinations with various treatments.

How to take

Adult dose

Type 2 diabetes mellitus Monotherapy and add-on combination therapy The recommended dose of this medicine is 10mg once daily for monotherapy and add-on combination therapy with other glucose-lowering agents, such as insulin. When this medicine is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. Initial combination therapy For patients who have not previously received pharmacological treatment for diabetes, when this medicine is administered in combination with metformin, the recommended initial dose is 5mg once daily or 10mg once daily. Special populations Renal impairment - eGFR less than 45 mL/min/1.73m2: Use of this medicine to improve glycemic control is not recommended. - Patients on dialysis: Do not administer this medicine. Hepatic impairment No dose adjustment is required for patients with mild or moderate hepatic impairment. For patients with severe hepatic impairment, a starting dose of 5 mg is recommended. If well tolerated, this dose may be increased to 10mg. Elderly patients (≥ 65 years) Dose adjustment based on age is not recommended. Method of administration This medicine may be administered orally once daily at any time of day, with or without food. The tablet should be swallowed whole.

Child dose

The efficacy and safety of dapagliflozin in children under 18 years of age have not been established. No relevant data are available.

Precautions

This medication should not be used in patients who have experienced allergic reactions to the active ingredients or excipients. It may pose risks for patients with type 1 diabetes or diabetic ketoacidosis. Since it contains anhydrous lactose, it should not be used in patients with genetic issues such as galactose intolerance, lactase deficiency, or glucose-galactose malabsorption. This medication is also not recommended for patients undergoing dialysis. In patients with reduced fluid volume or impaired kidney function, it may cause blood pressure reduction or kidney damage, so the patient's condition should be meticulously checked before administration and carefully monitored afterward. This medication contains certain colorants, Tartrazine and Sunset Yellow, so caution should be exercised in patients allergic to these substances. During the use of this medication, genital infections or urinary tract infections may occur; patients should immediately inform their healthcare provider if infection symptoms appear. There is a risk of hypoglycemia; therefore, when used with blood sugar-lowering agents such as insulin or sulfonylureas, blood sugar reduction symptoms should be closely monitored. Dehydration or hypotension symptoms may occur due to reduced fluid volume, so adequate fluid intake and careful observation of symptoms are essential. Serious metabolic abnormalities like diabetic ketoacidosis may occur; symptoms such as vomiting, abdominal pain, or difficulty breathing require immediate hospital attention. Blood sugar control effectiveness varies based on kidney function, so it is advisable to avoid use in patients with severe kidney impairment. Pregnant women or those planning to become pregnant should preferably not use this medication, and breastfeeding women should also avoid its use. Elderly patients or those with weakened kidney functions require special caution and, if necessary, blood pressure and kidney functions should be checked frequently. While taking this medication, caution should be exercised regarding hypoglycemic symptoms when driving or operating machinery. In case of overdose, there is no specific antidote, so appropriate treatment based on symptoms is important. This medication should be stored safely and kept out of the reach of children.

Side effects

Vulvovaginitis, balanitis and related genital infections, urinary tract infections, fungal infections, perineal necrosis, hypoglycemia, decreased fluid volume, thirst, diabetic ketoacidosis, dizziness, constipation, dry mouth, back pain, dysuria, polyuria, nocturia, interstitial nephritis, vulvar itching, genital itching, increased hematocrit, decreased creatinine clearance at the beginning of treatment, dyslipidemia, increased serum creatinine at the beginning of treatment, elevated blood urea, weight loss, acute pyelonephritis, rash, angioedema, urinary sepsis, pyelonephritis, acute kidney injury, renal dysfunction, asthenia, pain, keratitis, chronic obstructive pulmonary disease, hemoptysis, cerebral hemorrhage, peripheral artery occlusion, angina pectoris, myocardial infarction, bile duct stones, cholangitis, alcoholic cirrhosis, depression, suicide attempts, adenocarcinoma of the stomach, anaphylactic reaction, paresthesia, cerebral infarction, nerve compression, urinary tract infection, sinusitis, diverticulitis, pelvic inflammatory disease, pneumonia, pulmonary tuberculosis, asthenia, ligament sprain, urticaria, cold sweat, chest pain, fatigue, chest discomfort, vaginal discharge, menstrual irregularities, pruritus, arthralgia, musculoskeletal pain, limb pain, muscle weakness, myalgia, osteoarthritis, diabetic retinopathy, cough, dyspnea, orthostatic hypotension, palpitations, insomnia, fatty liver, gallbladder polyps, tinnitus

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to prevent exposure to air or moisture, ideally at room temperature between 1 to 30 degrees Celsius. This helps maintain the drug's effectiveness over time.

Appearance and packaging

Appearance

Yellow, round, film-coated tablet with convex sides on both sides

Package unit

28 tablets/box [28 tablets (7 tablets/PTP×4)]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.